Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR and allo-immunity; Saving platelet resources and reducing blood burden.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Platelet Transfusion Refractoriness

NCT number NCT05761457
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Yue Han, PhD,MD
Phone 13901551669
Email hanyue@suda.edu.cn
Status Recruiting
Phase N/A
Start date March 1, 2023
Completion date January 10, 2025

See also
  Status Clinical Trial Phase
Completed NCT02858323 - Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion
Recruiting NCT06254560 - Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness Phase 2
Recruiting NCT05399693 - Platelet Transfusion Refractoriness
Recruiting NCT04846439 - Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL Phase 1/Phase 2
Recruiting NCT05832216 - Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia Phase 1